Up-regulation of a constitutively active form of the β2-adrenoceptor by sustained treatment with inverse agonists but not antagonists

FEBS Letters

Volumn 399, Issue 1-2, 1996, Pages 108-112

  MacEwan, David J ^a   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Beta adrenoceptor; Constitutively active mutant; Inverse agonist

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; BETA 2 ADRENERGIC RECEPTOR; BETAXOLOL; BUCLADESINE; CYCLIC AMP; DIHYDROALPRENOLOL; ILOPROST; PROPRANOLOL; SOTALOL; TIMOLOL;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION; GENE TRANSFER; GLIOMA; HUMAN; HYBRID CELL; NERVE CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ADRENERGIC BETA-ANTAGONISTS; CYCLIC AMP; HUMANS; HYBRID CELLS; RECEPTORS, ADRENERGIC, BETA-2; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0030577361     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(96)01300-2     Document Type: Article

References (28)

1. [1] Schutz, W. and Freissmuth, M. (1992) Trends Pharmacol. Sci. 13, 376-380.
2. [2] Milligan, G., Bond, R.A. and Lee, M.G. (1995) Trends Pharmacol. Sci. 16, 10-13.
3. [3] Black, J.W. and Shankley, N.P. (1995) Nature 374, 214-215.
4. [4] Braestrup, C, Schmiechen, R., Neef, G., Nielsen, M. and Petersen, E.N. (1982) Science 216, 1241-1243.
5. [5] Samama, P., Cotecchia, S., Costa, T. and Lefkowitz, R.J. (1993) J. Biol. Chem. 268, 4625-1636.
6. [6] Ren, Q., Kurose, H., Lefkowitz, R.J. and Cotecchia, S. (1993) J. Biol. Chem. 268, 16483-16487.
7. [7] Lefkowitz, R.J., Cotecchia, S., Samama, P. and Costa, T. (1993) Trends Pharmacol. Sci. 14, 303-307.
8. [8] Gunning, P., Leavitt, J., Muscat, G., Ng, S.Y. and Kedes, L. (1987) Proc. Natl. Acad Sci. USA 84, 4831-4835.
9. [9] Adie, E.J. and Milligan, G. (1994) Biochem. J. 300, 709-715.
10. [10] Adie, E.J. and Milligan, G. (1994) Biochem. J. 303, 803-808.
11. [11] Milligan, G. (1987) Biochem. J. 245, 501-505.
12. [12] Milligan, G., Streaty, R.A., Gierschik, P., Spiegel, A.M. and Klee, W.A. (1987) J. Biol. Chem. 262, 8626-8630.
13. [13] Johnson, R.A. and Salomon, Y. (1991) Methods Enzymol. 195, 3-21.
14. [14] Milligan, G. and Unson, C.G. (1989) Biochem. J. 261, 837-841.
15. [15] Mitchell, F.M., Mullaney, I., Godfrey, P.P., Arkinstall, S.J., Wakelam, M.J.O. and Milligan, G. (1991) FEBS Lett. 287, 171-174.
16. [16] MacEwan, D.J., Kim, G.D. and Milligan, G. (1995) Mol. Pharmacol. 48, 316-325.
17. [17] Johnson, R.A., Yeung, S.-M.H., Stubner, D., Bushfield, M. and Shoshani, I. (1989) Mol. Pharmacol. 35, 681-688.
18. [18] Desaubry, L., Shoshani, I. and Johnson, R.A. (1996) J. Biol. Chem. 271, 2380-2382.
19. [19] Kobilka, B.K., Kobilka, T.S., Daniel, K., Regan, J.W., Caron, M.G. and Lefkowitz, R.J. (1988) Science 240, 1310-1316.
20. [20] Guan, X.-M., Amend, A. and Strader, C.D. (1995) Mol. Pharmacol. 48, 492-498.
21. [21] Pei, G., Samama, P., Lohse, M., Wang, M., Codina, J. and Lefkowitz, R.J. (1994) Proc. Natl. Acad. Sci. USA 91, 2699-2702.
22. [22] Milligan, G. (1993) Trends Pharmacol. Sci. 14, 413-418.
23. [23] Chambers, J., Park, J., Cronk, D., Chapman, C., Kennedy, F.R., Wilson, S. and Milligan, G. (1994) Biochem. J. 303, 973-978.
24. [24] van de Westerlo, E., Yang, J., Logsdon, C. and Williams, J.A. (1995) Biochem. J. 310, 559-563.
25. [25] Smit, M.J., Leurs, R., Alewijnse, A.E., Blauw, J., Van Nieuw Amerongen, G.P., Van de Vrede, Y., Roovers, E. and Timmerman, H. (1996) Proc. Natl. Acad. Sci. USA 93, 6802-6807.
26. [26] MacEwan, D.J. and Milligan, G. (1996) Mol. Pharmacol. (in press).
27. [27] Parent, J.-L., Le Gouill, C., de Brum-Fernandes, A.J., Rola-Pleszczynski, M. and Stankova, J. (1996) J. Biol. Chem. 271, 7949-7955.
28. [28] Perez, D.M., Hwa, J., Gaivin, R., Mathur, M., Brown, F. and Graham, R.M. (1996) Mol. Pharmacol. 49, 112-122.